Read more
Radioactive drug development is a multi-disciplinary task, therefore, in a concerted effort, dedicated scientists and experts from different fields of specialisation have contributed to this book. It is presented in two sections. Section 1 contains basic principles and methods used for analysis, information on the chemistry of technetium and on radiopharmaceuticals labelled with technetium-99m, the characteristics of the 99 Mo/99mTc-generator, of 'kits' and formulations for in-vitro labelling, and special safety aspects for in-vivo labelling of blood cells. Section 2 contains monographs of 99mTc-radiopharmaceuticals used in nuclear medicine. Each monograph includes information on the chemistry, formulation, commercial products and trade names, factors affecting in-vivo performance, clinical information on pharmacokinetics, as well as details concerning the clinical application and the radiation dose to patients.
List of contents
I.- Drug Safety.- Technetium in Medicine.- Stannous Chloride in the Preparation of 99mTc Pharmaceuticals.- Quality Assurance of Radiopharmaceuticals.- Performance and Quality Control of the 99Mo/99mTc Generator.- Preparation of Technetium 99mTc Pharmaceuticals.- Lyophilization Technique for Preparing Radiopharmaceutical Kits.- Cellular Labeling with 99mTc Chelates: Relevance of In Vitro and In Vivo Viability Testing.- Quality Control Methods of 99mTc Pharmaceuticals.- Other Technetium Isotopes: 94mTc as a Potential Substitute in Positron Emission Tomography Investigations.- The Rules Governing Medicinal Products for Human Use in the European Union.- II.- Monographs of 99mTc Pharmaceuticals.
Summary
Radioactive drug development is a multi-disciplinary task, therefore, in a concerted effort, dedicated scientists and experts from different fields of specialisation have contributed to this book. It is presented in two sections. Section 1 contains basic principles and methods used for analysis, information on the chemistry of technetium and on radiopharmaceuticals labelled with technetium-99m, the characteristics of the 99 Mo/99mTc-generator, of 'kits' and formulations for in-vitro labelling, and special safety aspects for in-vivo labelling of blood cells. Section 2 contains monographs of 99mTc-radiopharmaceuticals used in nuclear medicine. Each monograph includes information on the chemistry, formulation, commercial products and trade names, factors affecting in-vivo performance, clinical information on pharmacokinetics, as well as details concerning the clinical application and the radiation dose to patients.
Additional text
From the reviews:
"This nicely organized and clearly illustrated book provides an up-to-date resource for radiopharmacists and nuclear medicine physicians who compound and prescribe
99mTc-labeled radiopharmaceuticals. Radiochemists and those concerned with regulatory affairs also will be interested, and the book could be used as a primary text in nuclear medicine training programs. This outstanding book fills a void and is the first compilation of its kind in many years. We recommend it with the highest enthusiasm." (Susan Z. Lever and John R. Lever, Journal of Nuclear Medicine, May, 2009)
Report
From the reviews:
"This nicely organized and clearly illustrated book provides an up-to-date resource for radiopharmacists and nuclear medicine physicians who compound and prescribe 99mTc-labeled radiopharmaceuticals. Radiochemists and those concerned with regulatory affairs also will be interested, and the book could be used as a primary text in nuclear medicine training programs. This outstanding book fills a void and is the first compilation of its kind in many years. We recommend it with the highest enthusiasm." (Susan Z. Lever and John R. Lever, Journal of Nuclear Medicine, May, 2009)
